Resmed

뉴스

Reuters - 1 주 전

Australia shares slump more than 3% as US recession worries trigger sell-off

Australia shares slump more than 3% as US recession worries trigger sell-off ASX 200 posts worst session since June 2022 ASX volatility index at more than 2-year high Tech stocks lose 6.6%, financials drop 5% RBA policy decision due on Tuesday Updates to close By Himanshi Akhand and Rajasik Mukherjee Aug 5 (Reuters) - Australian shares slumped more than 3% in their worst trading session in over two years on Monday, joining a global sell-off in riskier assets after weak U.S.

Reuters - 1 주 전

Australia-listed shares of ResMed climb to 1-year high as analysts hike PT

BUZZ-Australia-listed shares of ResMed climb to 1-year high as analysts hike PT ** ASX-listed shares of ResMed RMD.AX RMD.N rise as much as 7% to A$34.020, their highest since Aug 2, 2023 ** Analysts at J.P. Morgan lift their price target on the medical equipment maker to A$37 from A$34.5 after its quarterly results ** Macquarie analysts raise PT to A$36.25 from A$35.40 ** U.S.-based co on Friday reported adj.

Reuters - 2 주 전

Resmed Inc reports results for the quarter ended in January - Earnings Summary

Resmed Inc reports results for the quarter ended in January - Earnings Summary Resmed Inc RMD.N reported quarterly adjusted earnings of $2.08 per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of $1.60. The mean expectation of twelve analysts for the quarter was for earnings of $2.07 per share.

Reuters - 2 주 전

Resmed Inc reports results for the quarter ended in June - Earnings Summary

Resmed Inc reports results for the quarter ended in June - Earnings Summary Resmed Inc RMD.N reported quarterly adjusted earnings of $2.08 per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $1.60. The mean expectation of twelve analysts for the quarter was for earnings of $2.07 per share.

Reuters - 2 주 전

ResMed meets estimates on steady demand for its sleep apnea devices

ResMed meets estimates on steady demand for its sleep apnea devices Aug 1 (Reuters) - Medical equipment maker ResMed RMD.N reported fourth-quarter revenue in line with estimates on Thursday, on steady demand for its sleep apnea treatment devices. The company's quarterly revenue rose 9% to $1.22 billion, in line with estimates of $1.22 billion. ResMed makes ventilators and machines that provide continuous and bilateral positive airway pressure, known as CPAP and BIPAP, which are used for non-inva